The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase I study of SEA-CD40, gemcitabine, nab-paclitaxel, and pembrolizumab in patients with metastatic pancreatic ductal adenocarcinoma (PDAC).
 
Andrew L. Coveler
Consulting or Advisory Role - Abbvie; Halozyme; Merrimack; Seagen
Research Funding - AbGenomics International (Inst); Amgen (Inst); Amgen (Inst); Genentech (Inst); Gilead Sciences (Inst); Halozyme (Inst); Immunomedics (Inst); Lilly (Inst); MedImmune (Inst); Newlink Genetics (Inst); Novocure (Inst); Onconova Therapeutics (Inst); Seagen (Inst); Taiho Pharmaceutical (Inst); XBiotech (Inst)
Travel, Accommodations, Expenses - Abbvie; Halozyme
 
David Lawrence Bajor
Consulting or Advisory Role - BridgeBio Pharma; Cardinal Health
Research Funding - Apexigen; Roche/Genentech; Seagen; Tesaro
 
Ashiq Masood
Honoraria - Boehringer Ingelheim; Bristol-Myers Squibb
Speakers' Bureau - Boehringer Ingelheim; Bristol-Myers Squibb
Research Funding - Astellas Pharma (Inst); Boston Biomedical (Inst); Calithera Biosciences (Inst); CytomX Therapeutics (Inst); Debiopharm Group (Inst); Debiopharm Group (Inst); Exelixis (Inst); Genentech/Roche (Inst); Ipsen (Inst); Macrogenics (Inst); Merck (Inst); Novocure (Inst); PRA Health (Inst); Proteus Digital Health (Inst); Seagen (Inst); Signatera (Inst)
 
Emrullah Yilmaz
No Relationships to Disclose
 
Anthony Frank Shields
Consulting or Advisory Role - Caris Life Sciences; ImaginAb; TransTarget
Speakers' Bureau - Caris Life Sciences
Research Funding - Astellas Pharma; AstraZeneca; Bayer; Boehringer Ingelheim; Boston Biomedical; Caris Life Sciences; Daiichi Sankyo; Eisai; Esperas Pharma; Esperas Pharma; Exelixis; Five Prime Therapeutics; H3 Biomedicine; Halozyme; ImaginAb; Incyte; Inovio Pharmaceuticals; Lexicon; LSK BioPharma; MSK Pharma; Nouscom; Plexxikon; Taiho Pharmaceutical; Torque; Xencor
Travel, Accommodations, Expenses - Caris Life Sciences; GE Healthcare; ImaginAb; Inovio Pharmaceuticals; TransTarget
 
Milind M. Javle
Consulting or Advisory Role - incyte; Mundipharma; oncosil; QED Therapeutics
Other Relationship - Bayer; BeiGene; Incyte; Merck; Merck Serono; Novartis; Pieris Pharmaceuticals; QED Therapeutics; Rafael Pharmaceuticals; Seagen
 
Ravi Kumar Paluri
Honoraria - Amgen; Ipsen
Speakers' Bureau - Ipsen
 
Gina M. Vaccaro
Consulting or Advisory Role - Alexion Pharmaceuticals; Amgen; Astellas Pharma; AstraZeneca; Bayer; Celgene; Exelixis; Genentech; Incyte; Novartis; Taiho Pharmaceutical
Research Funding - Array BioPharma; Astellas Pharma; Boston Scientific; Bristol-Myers Squibb; Celgene; EMD Serono; Incyte; Lilly; Merck Sharp & Dohme; Newlink Genetics; Polaris
 
Mark Zalupski
Research Funding - AstraZeneca/MedImmune; Halozyme; Merck; Newlink Genetics/Pharmatech; Oncomed; Seagen
 
Juneko E. Grilley-Olson
Consulting or Advisory Role - Bayer; Chimerix
Research Funding - Genentech (Inst); MedImmune (Inst); NanoCarrier (Inst); Pfizer (Inst); Seagen (Inst)
 
Hedy L. Kindler
Honoraria - AstraZeneca
Consulting or Advisory Role - Aldeyra Therapeutics; Astellas Pharma; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Deciphera; ERYTECH Pharma; Five Prime Therapeutics; Inventiva Pharma; Inventiva Pharma; ipsen; Kyowa Hakko Kirin; Merck; Paradox Therapeutics
Research Funding - Aduro Biotech (Inst); AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Deciphera (Inst); GlaxoSmithKline (Inst); Inhibrx (Inst); Leap Therapeutics (Inst); Lilly (Inst); Macrogenics (Inst); MedImmune (Inst); Merck (Inst); Polaris (Inst); Polaris (Inst); Roche/Genentech (Inst); Tesaro (Inst); Verastem (Inst)
Travel, Accommodations, Expenses - AstraZeneca
 
Michael W. Schmitt
Employment - Seagen
Stock and Other Ownership Interests - Seagen; TwinStrand Biosciences
 
Martin Gutierrez
Stock and Other Ownership Interests - Cota Healthcare
Honoraria - Foundation Medicine; Guardant Health
Consulting or Advisory Role - Exenex
Speakers' Bureau - Bristol-Myers Squibb; Lilly; Merck
Research Funding - Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Checkpoint Therapeutics (Inst); Eisai (Inst); GSB Pharma (Inst); Incyte (Inst); Johnson & Johnson (Inst); MedImmune (Inst); Merck (Inst); Moderna Therapeutics (Inst); NextCure (Inst); Pfizer (Inst); Regeneron (Inst); Roche/Genentech (Inst); Sanofi (Inst); Seagen (Inst); Silenseed (Inst)
Travel, Accommodations, Expenses - Guardant Health